LMLiang Ma

Liang Ma

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Liang Ma has a total of 22 co-authors. Here are the top co-authors by number of shared publications:

  • Wenzhao Wang

    Department of Orthopedic, Qilu Hospital of Shandong University, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China; Department of Orthopedics, West China Hospital, Sichuan University, Chengdu, Sichuan, China

    2 shared publications
  • Bingyang Yan

    First Clinical Medical School Shandong University of Traditional Chinese Medicine 250011 Jinan Shandong China

    1 shared publication
  • Boqing Zhang

    National Engineering Research Center for Biomaterials, Sichuan University, Chengdu, Sichuan, China

    1 shared publication
  • Chang Liu

    Department of Neurosurgery, the First Affiliated Hospital of Chongqing Medical University, Chongqing, China

    1 shared publication
  • Chuanxin Wang

    Department of Orthopedics Affiliated Hospital of Shandong University of Traditional Chinese Medicine 250014 Jinan Shandong China

    1 shared publication
  • Di Luo

    Department of Orthopedics Affiliated Hospital of Shandong University of Traditional Chinese Medicine 250014 Jinan Shandong China

    1 shared publication

Latest Publications

  • Open Access

    The causal relationship between epigenetic aging and osteoporosis: a bi-directional Mendelian randomization study

    by Chuanxin Wang, Wenfei Wu, Bingyang Yan, Di Luo, Yanbo Guo, Haisheng Yu, Wenzhao Wang, Liang Ma

    Aim: Osteoporosis (OP) is the most common of the musculoskeletal disorders, with decreased bone mineral density (BMD) being the main manifestation and exacerbating fracture susceptibility. OP was once thought to be an inevitable consequence of aging. We conducted a bi-directional Mendelian randomization (MR) for epigenetic age acceleration (EAA) and osteoporosis to accurately assess the interaction between aging and osteoporosis. Methods: This study collected data from genome-wide association studies of EAA and OP and assessed significant genetic variables. Bi-directional MR analyses were performed using random-effects inverse-variance weighting as the primary method, and the interaction of epigenetic age acceleration with OP was assessed using other MRI methods and multiple sensitivity analyses. Results: Inverse-variance weighted (IVW) results suggest that GrimAge acceleration accelerates bone loss in total body bone mineral density [odds ratio (OR) = 1.035, 95% confidence interval (95%CI) = (1.003, 1.069), P = 0.033]. The effect of BMD on EAA was investigated, and a causal relationship was found between forearm bone mineral density and GrimAge acceleration [OR = 0.682, (95%CI) = (0.508, 0.916), P = 0.011]. There was a causal relationship between femoral neck bone mineral density and PhenoAge acceleration [OR = 1.452, (95%CI) = (1.007, 2.096), P = 0.046]. Conclusions: Epigenetic age acceleration was bi-directionally causally associated with osteoporosis. GrimAge acceleration increased the risk of decreased total body bone mineral density. Forearm bone mineral density accelerated GrimAge and femoral neck bone mineral density accelerated PhenoAge acceleration.


  • Open Access

    CircRNA CDR1as affects functional repair after spinal cord injury and regulates fibrosis through the SMAD pathway

    by Wenzhao Wang, Chang Liu, Dong He, Guidong Shi, Ping Song, Boqing Zhang, Tian Li, Jianlu Wei, Yunpeng Jiang, Liang Ma


  • Open Access

    Blosozumab in the treatment of postmenopausal women with osteoporosis: a systematic review and meta-analysis

    by Yanlin Su, Wenzhao Wang, Fei Liu, Yuli Cai, Nianhu Li, Hao Li, Gang Li, Liang Ma

    Background: Postmenopausal women are one of the most vulnerable groups to osteoporosis. Romosozumab is a newly monoclonal drug that inhibits the activity of sclerostin. Since it has been on the market for only 3 years, there is a lack of systematic analysis on postmenopausal women and the efficacy is not clear. In this study, we compared randomized controlled trials to assess the effects of blosozumab versus placebo in perimenopausal and postmenopausal women. Methods: This meta-analysis has been registered in the PROSPERO registry (number CRD42020145839). The PubMed, Cochrane Library, ClinicalKey, and Embase databases were searched from inception date to July 01, 2021. We used the keywords “osteoporosis”, “decreased bone mass”, and “blosozumab” to retrieve studies on the relationship between blosozumab and osteoporosis in each database. The inclusion criteria were: (I) randomized controlled trials (RCTs) comparing the treatment of osteoporosis with blosozumab and a placebo or without treatment, (II) studies on postmenopausal women aged over 50 years, and (III) studies providing bone mineral density data. The quality of all randomized controlled trials included in this study was independently assessed by two researchers according to the Cochrane risk manual and was divided into high, medium and low quality. The main results analyzed were bone mineral density (BMD) and T-score. Our results mainly include BMD and procollagen type I N-terminal propeptide (P1NP), C-terminal telopeptide of type I collagen (CTX), bone-specific alkaline phosphatase (BSAP), and osteocalcin (OC). Results: Three RCTs with 105 patients were selected from 157 retrieved articles. Due to high heterogeneity [BMD: Tau2=2.79; Chi2=11.70, degrees of freedom (df) =1 (P=0.0006); I2=91%], we could not perform statistical analysis of BMD. The results of BMD were then evaluated systematically. Three RCT studies were included in the evaluation. Compared with that of the placebo, blosozumab increased levels of the BMD biomarker osteocalcin [mean deviation (MD) 12.55; 95% confidence interval (CI), 8.18, 16.91; PConclusions: The results suggested that blosozumab could be used as a target drug to improve BMD in postmenopausal women. This will provide a reference for the clinical treatment of postmenopausal women with osteoporosis.